Republic of the Congo (Concluded)

Analysis of MDA for LF in L. Loa Endemic Countries

Optimization of Mass Drug Administration with Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Congo Brazzaville

Study Site: Bouenza

The purpose of this community study is to determine the impact of MDA with Albendazole (400 mg, twice per year) on LF and STH in Central Africa. Interim results from this project are very encouraging regarding the potential of albendazole alone to control LF and STH. Preliminary results from the community trial are reported in a paper that has been accepted for publication in the American Journal of Tropical Medicine and Hygiene. The final re-examination was completed in 2015. Final lab results are currently being analyzed.

Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo
Lancet Infect Dis. 2017;17(7):763-769

Familial aggregation and heritability of Wuchereria bancrofti infection
J. Infect. Dis. 2016;214:587-594

The Impact of Two Semi-annual Treatments with Albendazole Alone on Lymphatic Filariasis and Soil-Transmitted Helminth Infections: A Community-based Study in the Republic of Congo
Am J Trop Med Hyg. 2015;92(5):959-966

A case study of risk factors for lymphatic filariasis in the Republic of Congo
Parasit Vectors. 2014;7:300

Short Report: Semi-Quantitative Scoring of an Immunochromatographic Test for Circulating Filarial Antigen
Am J Trop Med Hyg. 2013;89(5):916-918

Research Collaborator

Ministry of Health and Population
Brazzaville, Congo
Dr. Francois Missamou, Director of Epidemiology & Disease Control

Coordinating Institution

Institut de Recherche pour le Developpment Montpellier, France
Dr. Michel Boussinesq, Directeur de Recherche